Literature DB >> 20524772

Functional recovery after transplantation of bone marrow-derived human mesenchymal stromal cells in a rat model of spinal cord injury.

Rakhi Pal1, Chaitanya Gopinath, Nagesh M Rao, Poulomi Banerjee, Venkatesh Krishnamoorthy, Neelam K Venkataramana, Satish Totey.   

Abstract

BACKGROUND AIMS: Spinal cord injury (SCI) is a medically untreatable condition for which stem cells have created hope. Pre-clinical and clinical studies have established that these cells are safe for transplantation. The dose dependency, survivability, route of administration, cell migration to injury site and effect on sensory and motor behavior in an SCI-induced paraplegic model were studied.
METHODS: A spinal cord contusion injury model was established in rats. Bone marrow (BM) mesenchymal stromal cells (MSC) were tagged to facilitate tracing in vivo. Two different doses (2 and 5 million cells/kg body weight) and two different routes of infusion (site of injury and lumbar puncture) were tested during and after the spinal shock period. The animals were tested post-transplantation for locomotor capacity, motor control, sensory reflex, posture and body position. Stem cell migration was observed 1 month post-transplantation in spinal cord sections.
RESULTS: The overall results demonstrated that transplantation of BM MSC significantly improved the locomotor and sensory behavior score in the experimental group compared with the sham control group, and these results were dose dependent. All the infused stem cells could be visualized at the site of injury and none was visualized at the injected site. This indicated that the cells had survived in vivo, were probably chemoattracted and had migrated to the lesion site.
CONCLUSIONS: MSC transplanted with a lumbar puncture method migrate to the site of injury and are the most suitable for SCI healing. These cells demonstrate a dose-dependent effect and promote functional recovery when injected during or after the spinal shock period.

Entities:  

Mesh:

Year:  2010        PMID: 20524772     DOI: 10.3109/14653249.2010.487899

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  23 in total

Review 1.  Allogeneic and xenogeneic transplantation of adipose-derived stem cells in immunocompetent recipients without immunosuppressants.

Authors:  Ching-Shwun Lin; Guiting Lin; Tom F Lue
Journal:  Stem Cells Dev       Date:  2012-07-03       Impact factor: 3.272

2.  Aortic implantation of mesenchymal stem cells after aneurysm injury in a porcine model.

Authors:  Irene C Turnbull; Lahouaria Hadri; Kleopatra Rapti; Mikel Sadek; Lifan Liang; Hyun J Shin; Kevin D Costa; Michael L Marin; Roger J Hajjar; Peter L Faries
Journal:  J Surg Res       Date:  2011-07-13       Impact factor: 2.192

3.  Allogeneic Mesenchymal Stem Cells for Treatment of AKI after Cardiac Surgery.

Authors:  Madhav Swaminathan; Mark Stafford-Smith; Glenn M Chertow; David G Warnock; Viken Paragamian; Robert M Brenner; François Lellouche; Alison Fox-Robichaud; Mohamed G Atta; Spencer Melby; Ravindra L Mehta; Ron Wald; Subodh Verma; C David Mazer
Journal:  J Am Soc Nephrol       Date:  2017-10-16       Impact factor: 10.121

Review 4.  Neurotrauma and mesenchymal stem cells treatment: From experimental studies to clinical trials.

Authors:  Ana Maria Blanco Martinez; Camila de Oliveira Goulart; Bruna Dos Santos Ramalho; Júlia Teixeira Oliveira; Fernanda Martins Almeida
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

Review 5.  Mesenchymal stem cells secretome: a new paradigm for central nervous system regeneration?

Authors:  Fábio G Teixeira; Miguel M Carvalho; Nuno Sousa; António J Salgado
Journal:  Cell Mol Life Sci       Date:  2013-03-01       Impact factor: 9.261

Review 6.  Concise review: the potential of stromal cell-derived factor 1 and its receptors to promote stem cell functions in spinal cord repair.

Authors:  Anne Jaerve; Jessica Schira; Hans Werner Müller
Journal:  Stem Cells Transl Med       Date:  2012-10-10       Impact factor: 6.940

7.  Immortalized mesenchymal stem cells: an alternative to primary mesenchymal stem cells in neuronal differentiation and neuroregeneration associated studies.

Authors:  Min Gong; Yang Bi; Wei Jiang; Yun Zhang; Li Chen; Nali Hou; Youxue Liu; Xiaoping Wei; Jie Chen; Tingyu Li
Journal:  J Biomed Sci       Date:  2011-11-25       Impact factor: 8.410

8.  Bilateral transplantation of allogenic adult human bone marrow-derived mesenchymal stem cells into the subventricular zone of Parkinson's disease: a pilot clinical study.

Authors:  N K Venkataramana; Rakhi Pal; Shailesh A V Rao; Arun L Naik; Majahar Jan; Rahul Nair; C C Sanjeev; Ravindra B Kamble; D P Murthy; Krishna Chaitanya
Journal:  Stem Cells Int       Date:  2012-03-13       Impact factor: 5.443

9.  Phylogenetic distinction of iNOS and IDO function in mesenchymal stem cell-mediated immunosuppression in mammalian species.

Authors:  J Su; X Chen; Y Huang; W Li; J Li; K Cao; G Cao; L Zhang; F Li; A I Roberts; H Kang; P Yu; G Ren; W Ji; Y Wang; Y Shi
Journal:  Cell Death Differ       Date:  2013-10-25       Impact factor: 15.828

10.  Human umbilical cord blood-derived mesenchymal stem cell transplantation for the treatment of spinal cord injury.

Authors:  Bingzhou Cui; En Li; Bo Yang; Bo Wang
Journal:  Exp Ther Med       Date:  2014-03-06       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.